Our work, by preforming a 289 immune-related gene panel NanoString assay, has shown statistically increased PD-1, PD-L1, LAG3, TIGHT, and IDO1 expression in responders even in this very small group of patients, indicating that patients harboring a highly immune tolerance tumor microenvironment may benefit from the immunochemical therapy. The gene discussed is CD274; the disease is neoplasm.